Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biocryst Pharmaceuticals

8.76
-0.1200-1.35%
Post-market: 8.800.0400+0.46%17:36 EDT
Volume:2.42M
Turnover:21.15M
Market Cap:1.83B
PE:-33.76
High:8.87
Open:8.87
Low:8.69
Close:8.88
Loading ...

BioCryst Pharmaceuticals CEO Takes On Finance Duties on Interim Basis

MT Newswires Live
·
11 Apr

BRIEF-Biocryst Pharmaceuticals Appoints Jon Stonehouse As Interim CFO & Interim Principal Accounting Officer - SEC Filing

Reuters
·
11 Apr

BioCryst CEO to serve as interim CFO

TIPRANKS
·
11 Apr

BioCryst Pharmaceuticals - on April 7, Jon P. Stonehouse Appointed Interim CFO & Interim Principal Accounting Officer - SEC Filing

THOMSON REUTERS
·
11 Apr

BioCryst Pharmaceuticals Price Target Maintained With a $15.00/Share by Needham

Dow Jones
·
10 Apr

RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX)

TIPRANKS
·
05 Apr

BioCryst reports inducement grants under Nasdaq listing rule

TIPRANKS
·
04 Apr

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
04 Apr

BioCryst to Present at Upcoming Investor Conference

GlobeNewswire
·
03 Apr

High Growth Tech Stocks In The US Market With Promising Potential

Simply Wall St.
·
28 Mar

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%

Simply Wall St.
·
19 Mar

The 4.9% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 295%

Simply Wall St.
·
18 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Elevance, Backblaze, Disney

Reuters
·
12 Mar

BUZZ-BioCryst takes legal action to defend rare genetic drug patent; shares fall

Reuters
·
11 Mar

BioCryst reports inducement grants under Nasdaq listing rule

TIPRANKS
·
06 Mar

BRIEF-Biocryst Pharmaceuticals Says CFO Anthony Doyle To Resign Effective April 9, 2025

Reuters
·
04 Mar

BioCryst Pharmaceuticals CFO Anthony Doyle to Step Down

MT Newswires Live
·
04 Mar

BioCryst CFO Anthony Doyle to resign, effective April 9

TIPRANKS
·
04 Mar

BioCryst Pharmaceuticals Inc - CFO Anthony Doyle to Resign Effective April 9, 2025

THOMSON REUTERS
·
04 Mar

BioCryst Pharmaceuticals Price Target Maintained With a $18.00/Share by Citizens Capital Markets

Dow Jones
·
03 Mar